Last month, plastic surgeons from around the world converged on New York to take part in the annual meeting of the American Society for Aesthetic Plastic Surgery (ASAPS). Held at the Javits Center, delegates and speakers took part in teaching seminars and interactive sessions, sharing in the latest and greatest surgical and non-surgical cosmetic procedures and, ultimately, deciding on which innovations they would carry forwards into their own practices.
The meeting showcased a number of new products, including Xeomin – a new toxin with similar properties to botulinum toxin type A (known more commonly as Botox and Dysport). Devoid of any proteins, however, experts believe Xeomin, which is made from incobotulinum toxin A, minimises the risk of any allergic reactions. Indicated for the improvement of moderate to severe frown lines in adults, Xeomin is yet to be approved for use in Australia.
Physicians were also able to review the latest platform claiming to deliver reliable outcomes for wrinkle reduction, body contouring and skin tightening. The Symphony RF (radiofrequency) delivers specific doses of controlled radio frequency energy to treatments areas around the body, either through a handpiece held to the skin, or with a tiny RF probe, which delivers the energy through a non-insulated tip. With a system capable of controlling the temperature of the delivery mechanism, the device promises greater control and accuracy over the delivery of energy.
When it came to surgical procedures, those surgeons who perform extensive procedures such as body lifts and abdominoplasty were interested to learn more about Xarelto – a new prescription drug designed to cut the risk of stroke, blood clots, deep vein thrombosis and pulmonary embolism. The hope is that Xarelto may also be useful in preventing complications in more extensive cosmetic procedures.
The use of fat was a hot topic of debate. After the event, HealthNewsDigest reported on the discussion surrounding fat transfer to the breasts – seen by some as an alternative to breast augmentation with implants. Although fat transfer is incapable of achieving the same volume increase as implants, many believe the fact that the procedure draws on the patient’s own material minimises any risk of long term complication. Surgeons also argued against any concerns that the adipose tissue might disguise breast cancer and delay its diagnosis.
“It is not something that will hide a breast cancer and it most certainly doesn’t cause one, and it can be used in a variety of settings,” one US plastic surgeon commented at the meeting.
Surgeons also spoke about the use of fat in facelift procedures – injecting fat as an adjunct procedure to augment areas of the face that have suffered volume loss – which is now reportedly becoming commonplace in the US.
The annual event provided a valuable forum for the presentation and discussion of innovative techniques and products. As with any new technologies, however, ongoing research will affirm whether or not any of the devices and techniques showcased in New York go on to become the next best thing.
 annual meeting, New York.){kind=link}